Public Participation

Some time ago DEA asked HHS, including FDA, for its views on kratom.

DEA never responded to CRE’s request for a copy of  the letter it sent to the FDA nor did CRE obtain a copy of the HHS response to the DEA.

CRE was and still is of the opinion that FDA was a major player in the potential listing of Kratom on Schedule I. It was for this reason that the CRE recommended that Kratom users submit to regulation by the FDA with an emphasis on dosage and purity.  CRE wanted the FDA to spend its time on  developing a sensible regulation not a legal strategy to ban kratom.

DEA provided a window, some sixteen months, for the kratom community to act before FDA acted on its own; unfortunately the kratom community did not capitalize on that opportunity.

N. B. To our committed and informed followers, we value your emails but since we are no longer actively engaged on this matter we prefer you provide your comments in the space provided below so as the entire kratom community can benefit from them.

We are most grateful for the many emails we have received asking us again to get involved in the kratom issue but that is not  possible.